ABVC BioPharma, Inc. (ABVC)
$0.9465
Rating:
Recommendation:
-
| Symbol | ABVC |
|---|---|
| Price | $0.9465 |
| Beta | 0.488 |
| Volume Avg. | 0.09M |
| Market Cap | 30.579M |
| Shares () | - |
| 52 Week Range | 0.86-11.69 |
| 1y Target Est | - |
| DCF Unlevered | ABVC DCF -> | |
|---|---|---|
| DCF Levered | ABVC LDCF -> | |
| ROE | -331.64% | Strong Sell |
| ROA | -180.74% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 63.36% | Buy |
| P/E | - | |
| P/B | 3.78 | Strong Buy |
Latest ABVC news
About
Download (Excel)ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.